English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We  analyzed the results of treatment with imatinib mesylate in 70 patients with  chronic-phase chronic myeloid leukemia who had previously been treated (with  second-line or higher imatinib), many of them in a late chronic phase. The  median follow-up period was 60.5 months (range 3-100 months). Our objective was  to assess the efficacy and safety of treatment. The mean dose was 400 mg per  day. The hematologic response rate was 92.1% at six months, while the  cumulative rates of major and complete cytogenetic responses were 73.6 and  66.3%, respectively. Molecular response rate improved slowly and steadily over  time, reaching 65.8% at 60 months, remaining stable for up to 96 months. The  five-year progression-free survival and overall survival were 84 and 89%,  respectively. Cytogenetic response by 12 months significantly correlated with  overall survival (P = 0.0007) and progression-free survival (P = 0.0280). Sokal  risk score did not differ significantly between subgroups. The medication was  well tolerated, with only 16% of patients showing hematologic toxicity grades 3  and 4. At the end of the assessment, 57% of the patients were still on imatinib  mesylate; most of those who discontinued treatment (17/30) did so because of  unsatisfactory response. Treatment with imatinib mesylate in previously treated  chronic-phase chronic myeloid leukemia induced durable responses in a high  proportion of patients and was related to satisfactory long-term and event-free  survival.

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil